[Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression].
OBJECTIVE
Ovarian neoplasms are very important problem in medicine, because they account for 23% of all female genital neoplasms, and they are the cause of 47% deaths among women suffering from gynecological cancers. Progression of neoplasmatic disease depends also on dynamism of angiogenesis, because better oxygen and nutrition substances supply increase tumor growth. To increase the tumor volume of 1 mm3, the development of new vessels is needed, and that also increases the risk of distant metastases.


OBJECTIVE
The aim of the study was the evaluation of clinical parameters compared with histological and laboratory findings in serous carcinomas. The research analyzed of angiogenesis level (antigen CD34) in patients with ovarian cancers and in control group.


METHODS
The material consisted of 41 cases of serous ovarian cancer. For clinical examinations we chose only patients who underwent primary surgical operation. The control group for CD34 levels were 15 patients with benign serous adenomas. The microscopic (200x) evaluation of blood vessel in paraffin samples were made by showing the reaction of endothelial CD34 antigen with DAKO serum (Monoclonal Mouse Anti Human CD34 class 1-N 1574 LSAB).


RESULTS
The level of statistical significance for grading and total vessels' area was p = 0.01 (G1--0.037 mm2, G2--0.019 mm2, G3--0.015 mm2). No difference in vascularity was observed at the level of total vascularisation of serous ovarian cancers (0.021 mm2) and in benign serous adenomas (0.023 mm2).


CONCLUSIONS
Among analysed clinical and laboratory parameters only histological grade (G) correlates significantly with the level of vascularisation of ovarian serous cancers.
Blok
Radosław
R
I Katedry i Kliniki Ginekologii i Połoznictwa AM we Wrocławiu.
Blok
Krystian
K
Jeleń
Michał
M
Gryboś
Marian
M
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016022:Case-Control Studies; D018284:Cystadenocarcinoma, Serous / Q000098:blood supply* / Q000276:immunology; D018293:Cystadenoma, Serous / Q000098:blood supply; D018450:Disease Progression; D004730:Endothelium, Vascular / Q000276:immunology / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000276:immunology; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors
D018952:Antigens, CD34; D014408:Biomarkers, Tumor